Editorial: Antifungal Pipeline: Build It Strong; Build It Better!

Front Cell Infect Microbiol. 2022 Mar 16:12:881272. doi: 10.3389/fcimb.2022.881272. eCollection 2022.

John R Perfect^{1

2}, Damian J Krysan^{3

4}, Maurizio Del Poeta^{5

6}, Anna M Selmecki⁷, Jessica C S Brown⁸, Leah E Cowen⁹

¹ Division of Infectious Diseases, Department of Medicine, Duke University Medical Center, Durham, NC, United States.
² Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, NC, United States.
³ Department of Pediatrics and Microbiology, Carver College of Medicine, University of Iowa, Iowa City, IA, United States.
⁴ Department of Immunology, Carver College of Medicine, University of Iowa, Iowa City, IA, United States.
⁵ Department of Microbiology and Immunology and Division of Infectious Diseases, Stony Brook University, Stony Brook, NY, United States.
⁶ Veterans Administration Medical Center, Northport, NY, United States.
⁷ Department of Microbiology and Immunology, University of Minnesota Medical School, Minneapolis, MN, United States.
⁸ Department of Pathology, Division of Microbiology and Immunology, University of Utah, Salt Lake City, UT, United States.
⁹ Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada.

No abstract available

Keywords: antifungal; drug-resistance; fungal disease; invasive fungal infection (IFI); pipeline.

Publication types